More Articles


Lowering the patient burden in clinical trials

Katie Osborne, (Mar 11, 2021)

Closer relationships with patients and a better understanding of what matters to them will show the way improving their experience of trials

Is COVID the gamechanger for decentralized trials?

Ulrich Neumann, (Mar 8, 2021)

There is a golden opportunity to deliver clinical trial innovation post-pandemic given healthcare’s appetite for new approaches, such as virtual patient consults and more efficient trial designs
Patients and Medical

The value in measuring the patient experience

Andrew Stone, (Feb 22, 2021)

Pharma can improve outcomes, products and HCP relationships using technology to capture patients’ day-to-day experience of their disease

Building capacity in digital

Katie Osborne, (Feb 22, 2021)

The new era of digital-first engagement demands new approaches to scaling by harnessing technology, seeing content creation as collaborative and cultivating a startup culture
Access and Evidence

Bringing innovation to rare disease patients in Europe

Izzy Gladstone, (Feb 17, 2021)

Johanna Friedl-Naderer, President, Europe, Canada & Partner Markets, Biogen on how collaboration between governments and industry can lead to better patient outcomes.
Access and Evidence

#Icare4Rare campaign launches to raise awareness ahead of Rare Disease Week 2021

Izzy Gladstone, (Feb 11, 2021)

To help raise awareness of rare disease, Reuters Events, Biogen and EU40 have collaborated to launch the #Icare4rare campaign to give prominence to Rare Disease Week 2021

Trial site management in the post pandemic era

Lucy Fulford, (Jan 26, 2021)

The impacts of 2020 on trials are causing pharma to consider a new direction for trial sites, taking them closer to the patient
Patients and Medical

Better research through patient insights

Andrew Stone, (Jan 26, 2021)

AstraZeneca’s innovations in chronic kidney disease are pointing the way to new ways of involving patients and RWE to drive new insights and better outcomes

Broadening participation in clinical trials: A win for all

Joseph Constance, (Jan 6, 2021)

Broader and deeper outreach, along with RWE, are some of the methods pharma is using to widen trials participation

Blended and augmented: Reimagining the role of the rep

Andrew Stone, (Dec 18, 2020)

The events of 2020 have compelled pharma to reimagine the role of the rep to better adapt to the new rules of engagement